In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Pharmaceuticals, Inc.

http://www.avanir.com

Latest From Avanir Pharmaceuticals, Inc.

Gyroscope Spins Forward With Dry AMD Gene Therapy

Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.

Gene Therapy Financing

Keeping Track: US FDA Approves J&J’s Novel MS Drug Ponvory, Breakthrough Pericarditis Claim For Kiniksa’s Arcalyst

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Regulation

Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals

Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds. 

Financing Innovation

Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach

With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.

Research and Development Strategies Deals
See All

Company Information

  • Other Names / Subsidiaries
    • Alamo Pharmaceuticals, LLC
UsernamePublicRestriction

Register